(2S)-3-methyl-2-(2-oxoethyl)butanoic acid | 149976-44-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (2S)-3-methyl-2-(2-oxoethyl)butanoic acid
• CAS: 149976-44-3
• 化学式: C₇H₁₂O₃
• 分子量: 144.17
• InChiKey: OLJLEDGHNXTSHH-LURJTMIESA-N

物化性质

• 沸点：
  250.5±23.0 °C(Predicted)
• 密度：
  1.054±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (2S)-3-methyl-2-(2-oxoethyl)butanoic acid 在 jones reagent 作用下， 以 丙酮 为溶剂， 生成 (S)-2-isopropylsuccinic acid
  参考文献：
  名称：

  The Power of Visual Imagery in Synthesis Planning. Stereocontrolled Approaches to CGP-60536B, a Potent Renin Inhibitor

  摘要：

  Two strategies were developed toward the stereocontrolled synthesis of 8-aryl-3-hydroxy-4-amino2,7-diisopropyloctanoic acids with predetermined stereogenic centers. This is a generic motif in a new class of potent inhibitors of the enzyme renin, exemplified by CGP-60536B. The synthesis relies on the utilization of L-pyroglutamic acid as chiron, and proceeds through the incorporation of required functionality by exploiting internal induction. One of the strategies shows the power of visual imagery in synthesis planning, akin to a Dali-like representation of objects that can be viewed in more than one way. Thus, the entire carbon skeleton of the target molecule is encompassed in a partially functionalized bicyclic indolizidinone precursor. In a second strategy, an intermediate common to the first approach is elaborated into an appended gamma-lactone which is alkylated through enolate chemistry and ultimately transformed into the intended target compound. X-ray crystallography was used to corroborate the structures and stereochemistries of several intermediates.

  DOI：

  10.1021/jo011184i
• 作为产物：
  描述：

  5-(bromomethyl)-3-isopropyldihydrofuran-2(3H)-one 在 sodium periodate 、 四氧化锇 、 水 、 锌 作用下， 以 四氢呋喃 、 水 、 异丙醇 为溶剂， 反应 5.0h， 生成 (2S)-3-methyl-2-(2-oxoethyl)butanoic acid
  参考文献：
  名称：

  The Power of Visual Imagery in Synthesis Planning. Stereocontrolled Approaches to CGP-60536B, a Potent Renin Inhibitor

  摘要：

  Two strategies were developed toward the stereocontrolled synthesis of 8-aryl-3-hydroxy-4-amino2,7-diisopropyloctanoic acids with predetermined stereogenic centers. This is a generic motif in a new class of potent inhibitors of the enzyme renin, exemplified by CGP-60536B. The synthesis relies on the utilization of L-pyroglutamic acid as chiron, and proceeds through the incorporation of required functionality by exploiting internal induction. One of the strategies shows the power of visual imagery in synthesis planning, akin to a Dali-like representation of objects that can be viewed in more than one way. Thus, the entire carbon skeleton of the target molecule is encompassed in a partially functionalized bicyclic indolizidinone precursor. In a second strategy, an intermediate common to the first approach is elaborated into an appended gamma-lactone which is alkylated through enolate chemistry and ultimately transformed into the intended target compound. X-ray crystallography was used to corroborate the structures and stereochemistries of several intermediates.

  DOI：

  10.1021/jo011184i

文献信息

• Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease
  申请人：Varghese John

  公开号：US20050159460A1

  公开（公告）日：2005-07-21

  The present invention relates to methods of treating Alzheimer's disease, and other diseases, and/or inhibiting beta-secretase enzyme, and/or inhibiting deposition of A beta peptide in a mammal, by use of known compounds of formula (I) wherein R 1 , R 2 , R 3 , U′, U″, V, Y, W, Q, R′ are as defined herein.

  本发明涉及使用式(I)中已知化合物的方法，其中R1、R2、R3、U'、U"、V、Y、W、Q、R'的定义如本文所述，用于治疗阿尔茨海默病和其他疾病，和/或抑制β-分泌酶酶，和/或抑制哺乳动物中Aβ肽的沉积。
• Renin Inhibitors
  申请人：Bayly Christopher I.

  公开号：US20090281103A1

  公开（公告）日：2009-11-12

  The present invention relates to novel renin inhibitors of the general Formula (I), and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds. These novel renin inhibitors are used in treating cardiovascular events and renal insufficiency.

  本发明涉及一种新型肾素抑制剂，其通式为（I），并且它们作为制备制药组合物的活性成分使用。该发明还涉及相关方面，包括化合物的制备过程。这些新型肾素抑制剂用于治疗心血管事件和肾功能不全。
• PEPTIDE ISOTERS CONTAINING A HETEROCYCLE AS H.I.V. INHIBITORS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP0603309A1

  公开（公告）日：1994-06-29
• PEPTIDE ISOSTERES CONTAINING A HETEROCYCLE USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE
  申请人：Elan Pharmaceuticals, Inc.

  公开号：EP1450795A1

  公开（公告）日：2004-09-01
• [EN] PEPTIDE ISOTERS CONTAINING A HETEROCYCLE AS H.I.V. INHIBITORS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：WO1993005026A1

  公开（公告）日：1993-03-18

  (EN) Novel compounds containing a heterocyclic isostere of formula (I) are disclosed, which inhibit the replication of the Human Immunodeficiency Virus.(FR) L'invention concerne de nouveaux composés contenant un isostère hétérocyclique de la formule (I), lesquels inhibent la réplication du virus de l'immunodéficience humaine.